Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin.  Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility.
Product Name: Oxaliplatin (CAS NO.61825-94-3)

Molecular Formula: C₈H₁₄N₂O₄Pt
Molecular Weight: 397.29g/mol
Mol File: 61825-94-3.mol
Appearance: White Crystalline Solid
Boiling point: 193.6 °C at 760 mmHg
Flash Point: 75 °C
Stability: Stable. Store cool. Incompatible with oxidizing agents.
Enthalpy of Vaporization: 42.98 kJ/mol
Vapour Pressure: 0.46 mmHg at 25°C
H-Bond Donor: 2
H-Bond Acceptor: 6
Structure Descriptors of Oxaliplatin (CAS NO.61825-94-3):
  IUPAC Name: (1R,2R)-cyclohexane-1,2-diamine; oxalate; platinum(4+)
  Canonical SMILES: C1CCC(C(C1)N)N.C(=O)(C(=O)[O-])[O-].[Pt+4]
  Isomeric SMILES: C1CC[C@H]([C@@H](C1)N)N.C(=O)(C(=O)[O-])[O-].[Pt+4]
  InChI: InChI=1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+4/p-2/t5-,6-;;/m1../s1 
  InChIKey: PCRKGXHIGVOZKB-BNTLRKBRSA-L
Product Categories: Pharmaceutical material and intermeidates; Active Pharmaceutical Ingredients; Antineoplastic; Intermediates & Fine Chemicals; Pharmaceuticals

Oxaliplatin was discovered in 1976 at Nagoya City University in Japan by Professor Yoshinori Kidani, who was granted U.S. Patent 4,169,846 over the drug in 1979. Oxaliplatin was subsequently in-licensed by Debiopharm, a Swiss drug company headquartered in Lausanne and developed as an advanced colorectal cancer treatment. Debio licensed the drug to Sanofi-Aventis in 1994. Eloxatin gained European approval in 1996 (firstly in France) and approval by the U.S. Food and Drug Administration (FDA) in 2002.

It is typically administered in combination with fluorouracil and leucovorin in a combination known as FOLFOX for the treatment of colorectal cancer.

Safety Information of Oxaliplatin (CAS NO.61825-94-3):
Hazard Codes: Xn,Xi
Risk Statements: 36/37/38-40-42/43  
R36/37/38:Irritating to eyes, respiratory system and skin. 
R40:Limited evidence of a carcinogenic effect. 
R42/43:May cause sensitization by inhalation and skin contact.
Safety Statements: 26-36
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. 
S36:Wear suitable protective clothing.
RIDADR: 2811
WGK Germany: 3
RTECS: TP2275850
HazardClass: 6.1(a)
PackingGroup: II

 Oxaliplatin , its CAS NO. is 61825-94-3, the synonyms are (SP-4-2-(1R-trans))-(1,2-Cyclohexanediamine-N,N')(ethanedioato(2-)-O,O')platinum ; Dacplat ; Eloxatin ; Elplat ; JM-83 ; Lipoxal ; Oxalato(1R,2R-cyclohexanediammine)platinum(II) ; Oxalato(trans-(-)-1,2-cyclohexanediamine)platinum(II) ; Oxalato(trans-1-1,2-cyclohexanediamine)platinum(II) ; Oxalatoplatinum ; UNII-04ZR38536J ; cis-((1R,2R)-1,2-Cyclohexanediamine-N,N')(oxalato(2-)-O,O')platinum ; trans-l-Diaminocyclohexane oxalatoplatinum ; Platinum, ((1R,2R)-1,2-cyclohexanediamine-.kappa.N,.kappa.N')(ethanedioato(2-)-kappaO1,kappaO2)-, (SP-4-2)- ; Platinum, (1,2-cyclohexanediamine-N,N')(ethanedioato(2-)-O,O')-, (SP-4-2-(1R-trans))- .